Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CDK2 inhibition produces a persistent population of polyploid cancer cells
Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky
Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky
View: Text | PDF
Research Article Oncology Therapeutics

CDK2 inhibition produces a persistent population of polyploid cancer cells

  • Text
  • PDF
Abstract

Aneuploidy, a cancer hallmark, drives chromosomal instability, drug resistance, and clinically aggressive tumors. Cyclin-dependent kinase 2 (CDK2) antagonism with independent inhibitors or CDK2 knockdown triggered anaphase catastrophe. This disrupts supernumerary centrosome clustering, causing multipolar division and apoptosis. Time-lapse fluorescence microscopy of fluorescent ubiquitination-based cell cycle indicator (FUCCI) cell cycle probes transduced into aneuploid lung cancer cells revealed distinct fates of bipolar and polyploid cells after CDK2 inhibition. Apoptosis occurred in multipolar progeny but was repressed in persistent polyploid cancer cells. RNA-Seq analyses after CDK2 inhibition of 4N versus 2N lung cancer cells were enriched for CDK1 pathway and KIF family members. The Cancer Genome Atlas (TCGA) analysis of lung cancers indicated that CDK1 and KIF family member overexpression was associated with an unfavorable survival. Intravital microscopy of transplanted lung cancer cells in mice extended findings from the in vitro to in vivo settings. CDK2 inhibition of tumor-bearing mice produced polyploid cancer cells in vivo. These cancer cells were resistant to apoptosis and proliferated despite CDK2 inhibition. In contrast, polyploid populations were rarely detected in CDK2-inhibited human alveolar epithelial cells. These findings are translationally relevant. Combined targeting of CDK2 with CDK1 or kinesin family member antagonists should eliminate polyploid cancer cells, promote apoptosis, and augment antineoplastic effects.

Authors

Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky

×

Figure 5

The characterization of multinucleated cells after CDK2 inhibition.

Options: View larger image (or click on image) Download as PowerPoint
The characterization of multinucleated cells after CDK2 inhibition.
(A) ...
(A) This schematic summarizes the cycling cancer cell fates: multipolar mitosis followed by cytokinesis failure, which gives rise to multinucleated cancer cells that can enter the next multipolar mitosis. (B) A representative image of a multinucleated cancer cell is shown by FIB-SEM. (C) Immunofluorescence staining of Lamin B1 for nuclear membrane confirmed the multinucleated phenotype. (D) Apoptotic cell death was enhanced by CYC065-treated mononucleated and multinucleated cancer cells (human H1299, A549, Hop62, and H522 as well as murine ED1SQ4 and 344SQ lung cancer cell lines), with multinucleated cancer cells having a statistically significant lower apoptosis rate than did mononucleated cells. (E) The ratios of multinucleated cancer cells/total cells remained stable during 8 days of CYC065 treatments in H1299 and ED1SQ4 cells. (F) Diploid (2N) and polyploid (4N) ED1SQ4 lung cancer cells were isolated by FACS for RNA-Seq analysis following vehicle or CYC065 treatment. (G) Volcano plots of differentially expressed genes caused by CYC065 as compared with vehicle treatment were displayed for diploid and polyploid cancer cells. Red dots indicate expressed genes with fold change > 2 or < 0.5 and with P < 0.05. Blue dots indicate expressed genes with fold change < 2 and > 0.5 and with P < 0.05. Green dots indicate expressed genes with P > 0.05. (H) Volcano plot and Venn diagram of the differentially expressed genes in polyploid versus diploid cancer cells augmented by CYC065 treatments are displayed. Differential gene expression analysis (G and H) was performed using a negative binomial model and Wald test with Benjamini-Hochberg correction to calculate adjusted P values. (I) Real-time PCR assays validated the representative differentially expressed genes (Ccnb1, Ccna2, Cdk1, Plk1, Aurka, Cdc25c, Cdc20, Kif18a, Kif2c, and Kifc1) increased in polyploid versus diploid cancer cells by CYC065 treatment. Two-tailed Student’s t tests compared differences between study groups in D, E, and I with a Bonferroni correction of P value below 0.05 deemed statistically significant. Data are shown as mean ± SD, with the symbols indicating *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, respectively. Scale bars: 20 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts